Methods and compositions for increasing hepcidin expession using modified iron binding/releasing transferrin
AssigneeNew York Blood Center, Inc.
InventorYelena Z. Ginzburg
Life of this patent
Estimating the term…
Abstract
Provided are methods for increasing hepcidin expression, treating a disorder associated with iron overload, decreasing non-transferrin bound iron (NTBI), reducing spleen size, ameliorating ineffective erythropoiesis, decreasing iron uptake by erythroid cells, and increasing transferrin receptor 1 (TfR1) expression in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a modified iron binding/releasing transferrin, wherein said modified iron binding/releasing transferrin comprises an N-lobe and a C-lobe, and wherein one of said lobes binds iron, and wherein one of said lobes has a decreased binding affinity for iron.
Claims32
A method for treating a disease or disorder associated with insufficient hepcidin expression or ineffective erythropoiesis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a modified iron binding/releasing transferrin (MI-Tf), wherein the MI-Tf is a transferrin (a) capable of binding only one iron molecule or (b) capable of binding two iron molecules and releasing only one iron molecule.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-15. (canceled)
-39. (canceled)
A pharmaceutical composition comprising a therapeutically effective amount of:
- an MI-Tf, wherein the MI-Tf is a transferrin (a) capable of binding only one iron molecule or (b) capable of binding two iron molecules and releasing only one iron molecule;
- and
- a pharmaceutically acceptable carrier.
-51. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.